Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1 Small Cell Lung Carcinoma 1

Interventions

apatinib 3 vistusertib 2 olaparib 2 camrelizumab 2 atezolizumab 2 Ipilimumab 2 Everolimus 2 trametinib 1 toripalimab 1 tilsotolimod 1 tazemetostat 1 tazarotene 1 spartalizumab 1 seviteronel 1 sargramostim 1 sacituzumab govitecan 1 rucaparib 1 roniciclib 1 romiplostim 1 pyrotinib 1 phosphorylethanolamine 1 pemigatinib 1 pembrolizumab 1 pazopanib 1 palbociclib 1 niraparib 1 magrolimab 1 lenvatinib 1 irinotecan sucrosofate 1 famitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor × roniciclib × Clear all

NCT02656849 2016-07-01

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡